The Life Sciences Report

"RP is currently in discussions with potential partnerships focused not just on the firm's injector, but also on its regenerative medicine therapies."

–Douglas Loe, Echelon Wealth Partners

"PMN announced that a third therapy has been identified for the firm's Alzheimer's disease pipeline."

–Douglas Loe, Echelon Wealth Partners

"INO announced positive (Phase 1b) data for INO-5150."

–Jason McCarthy, Maxim Group

"INO's INO-5150 generated T-cell responses in 60% of trial subjects."

–Ram Selvaraju, H.C. Wainwright & Co.

"INNV reported 99% top line growth for its second quarter."

–Ajay Tandon, SeeThruEquity

"One of the major operational items of interest since VIVE's Q1 update is an agreement with InControl Medical LLC."

–Brian Marckx, Zacks Equity Research

"RP announced its participation in the ThawSTAR Early Adopter Program."

–Douglas Loe, Echelon Wealth Partners

"DRRX confirmed that it expects to complete patient follow-up visits this quarter, and announce top-line results from the Phase 3 PERSIST study in 4Q17."

–Ed Arce, H.C. Wainwright & Co.

"We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019."

–Anthony Vendetti, Maxim Group

"We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."

–Jeff Cohen, Ladenburg Thalmann

"We continue to be optimistic about DRRX's story."

–Grant Zeng, Zacks Equity Research

"Highlights of DRRX's second quarter include reaching a commercialization agreement with Sandoz, completing enrollment of a pivotal Phase III trial for this asset, and completing drug-drug interaction studies and a Phase Ib trial for DUR-928."

–Patrick Dolezal, LifeSci Advisors

"INNV has been developing a promising growth engine in what appears to be a replicable process of identifying promising OTC products that target large markets—and then leveraging its Beyond Human sales platform."

–Jay Albany, SeeThruEquity

"INO initiated a phase III study to evaluate VGX-3100 for treatment of cervical dysplasia caused by human papillomavirus."

–Zacks Equity Research

"On the back of DRRX's solid deal with Sandoz and with more catalysts to come in 2017 such as Posimir Phase 3 readout in 4Q17 and IND filings for DUR-928, we see potential near-term upside."

–Francois Brisebois, Laidlaw & Company

"INO reported top-line revenues of $20.4M in 2Q17 handily beating our original projection."

–Ram Selvaraju, H.C. Wainwright & Co.

"INO is a pivotal company and multiple pipeline programs continue to advance."

–Jason McCarthy, Maxim Group

"INO reported 2Q17 financial results, including $92M in cash prior to the recent $71M capital raise."

–Charles Duncan, Piper Jaffray & Co.

"We have recently performed additional diligence on INO's REVEAL and believe the program is well-designed to demonstrate clinically meaningful results which highlight potential advantages over surgery."

–Charles Duncan, Piper Jaffray & Co.

"At the current price, we view RVX shares as undervalued, and in a position to provide long-term upside potential

–John Vandermosten, Zacks Equity Research